2.77

2.81% -0.08

Genelux Corp (GNLX)

Overview News Price History Why GNLX Down? Discussions Forecast

Genelux Corp stock is traded at $2.77, with a volume of 71,446. It is down -2.81% in the last 24 hours and up +7.78% over the past month. Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

Previous Close:

$2.85

Open:

$2.88

24h Volume:

71,446

Relative Volume:

0.38

Market Cap:

$124.21M

Revenue:

$8,000

Net Income/Loss:

$-32.15M

P/E Ratio:

-3.1986

EPS:

-0.866

Net Cash Flow:

$-26.37M

1W Performance:

+9.49%

1M Performance:

+7.78%

6M Performance:

-64.67%

1Y Performance:

+10.36%

1-Day Range:

$2.72

$2.9692

1-Week Range:

$2.46

$2.97

52-Week Range:

$2.255

$8.535

Genelux Corp Stock (GNLX) Company Profile

Name

Genelux Corp

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

805-267-9889

Address

2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE

Employee

Twitter

Next Earnings Date

2026-05-05

Latest SEC Filings

GNLX's Discussions on Twitter

Compare GNLX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GNLX Genelux Corp	2.77	124.21M	8,000	-32.15M	-26.37M	-0.866
VRTX Vertex Pharmaceuticals Inc	424.36	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.06B	5.36B	287.73M	924.18M	2.5229

Genelux Corp Stock (GNLX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-21-25	Initiated	Lake Street	Buy
Oct-29-24	Initiated	Guggenheim	Buy
Aug-28-24	Initiated	ROTH MKM	Buy
Nov-27-23	Initiated	H.C. Wainwright	Buy
Sep-12-23	Initiated	Maxim Group	Buy
Feb-15-23	Initiated	The Benchmark Company	Speculative Buy

View All

Genelux Corp Stock (GNLX) Latest News

May 02, 2026

GNLX SEC FilingsGenelux Corp 10-K, 10-Q, 8-K Forms - Stock Titan

May 02, 2026

May 01, 2026

Genelux Corp expected to post a loss of 18 cents a shareEarnings Preview - TradingView

May 01, 2026

Apr 29, 2026

[ARS] GENELUX Corp SEC Filing - Stock Titan

Apr 29, 2026

Genelux (NASDAQ: GNLX) details 2026 virtual meeting, board and auditor votes - Stock Titan

Apr 29, 2026

Apr 28, 2026

Genelux (GNLX) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat

Apr 28, 2026

Apr 23, 2026

GNLX Technical Analysis | Trend, Signals & Chart Patterns | GENELUX CORP (NASDAQ:GNLX) - ChartMill

Apr 23, 2026

Apr 22, 2026

Olvi Vec could reshape advanced ovarian cancer treatment, Genelux claims - Traders Union

Apr 22, 2026

Apr 17, 2026

Genelux advances next generation oncolytic immunotherapies for cancer treatment - Traders Union

Apr 17, 2026

Apr 11, 2026

Wall Street Zen Downgrades Genelux (NASDAQ:GNLX) to Sell - MarketBeat

Apr 11, 2026

Apr 09, 2026

Is Genelux Corporation (GNLX) Stock Good for Short Term | Price at $2.45, Down 7.20%Elite Trading Signals - Newser

Apr 09, 2026

Apr 03, 2026

GNLX Stock Analysis: Genelux Corporation Holds Near 2.57 Level With Modest Daily Gain - Newser

Apr 03, 2026

Apr 01, 2026

GNLX Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 01, 2026

Mar 31, 2026

Analyst Calls: Can Genelux Corporation outperform in the next rally2026 Market Outlook & AI Driven Price Predictions - baoquankhu1.vn

Mar 31, 2026

GNLX PE Ratio & Valuation, Is GNLX Overvalued - Intellectia AI

Mar 31, 2026

Mar 27, 2026

Genelux head of regulatory sells $1.4k in shares By Investing.com - Investing.com Australia

Mar 27, 2026

Mar 26, 2026

Yu Yong, Genelux SVP, sells $2192 in GNLX stock By Investing.com - in.investing.com

Mar 26, 2026

Genelux CEO Zindrick sells $8668 in shares By Investing.com - Investing.com South Africa

Mar 26, 2026

Genelux head of regulatory sells $1.4k in shares - investing.com

Mar 26, 2026

Cappello, Genelux CTO, sells $2192 in GNLX stock By Investing.com - Investing.com South Africa

Mar 26, 2026

Yu Yong, Genelux SVP, sells $2192 in GNLX stock - Investing.com

Mar 26, 2026

Genelux CEO Zindrick sells $8668 in shares - Investing.com

Mar 26, 2026

Genelux (GNLX) Head of Regulatory sells 585 shares to cover RSU taxes - Stock Titan

Mar 26, 2026

AI Stocks: Is Genelux Corporation showing insider buyingShort Setup & Technical Pattern Alert System - baoquankhu1.vn

Mar 26, 2026

Mar 23, 2026

FY2029 Earnings Estimate for Genelux Issued By HC Wainwright - MarketBeat

Mar 23, 2026

Mar 21, 2026

Genelux (NASDAQ:GNLX) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat

Mar 21, 2026

Genelux (NASDAQ:GNLX) Upgraded by Wall Street Zen to “Hold” Rating - Defense World

Mar 21, 2026

Mar 20, 2026

Genelux (NASDAQ:GNLX) Price Target Cut to $20.00 by Analysts at Benchmark - MarketBeat

Mar 20, 2026

Genelux: Advancing Olvi-Vec Pivotal Program and Manufacturing Readiness Underpin Buy Rating and Long-Term Value Upside - TipRanks

Mar 20, 2026

Genelux Corp 2024 Annual Report: Oncolytic Virus Pipeline, Olvi-Vec Clinical Trials, Strategy, Risks, and Competitive Landscape 66686970719293 - Minichart

Mar 20, 2026

Mar 19, 2026

Gap Down: Can Genelux Corporation be recession proof2026 Fundamental Recap & Reliable Entry Point Trade Alerts - baoquankhu1.vn

Mar 19, 2026

Genelux (NASDAQ: GNLX) launches $100M at-the-market program with TD Cowen - Stock Titan

Mar 19, 2026

Genelux Establishes $100 Million At-The-Market Equity Program - TipRanks

Mar 19, 2026

Genelux Corp reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 19, 2026

Genelux Establishes $100 Million ATM Equity Program With TD Cowen - TradingView

Mar 19, 2026

Genelux (NASDAQ: GNLX) launches $100M at-the-market stock plan - stocktitan.net

Mar 19, 2026

Genelux Corporation Announces Phase 3 Trial Data Timeline and Interim Results for Olvi-Vec in Ovarian and Lung Cancer, Alongside Leadership Appointment - Quiver Quantitative

Mar 19, 2026

[10-K] GENELUX Corp Files Annual Report | GNLX SEC FilingForm 10-K - Stock Titan

Mar 19, 2026

GENELUX 2025 10-K: Revenue $0.01M, Net Loss $32.1M - tradingview.com

Mar 19, 2026

Cancer drug readout nears as Genelux says cash lasts into 2027 - Stock Titan

Mar 19, 2026

Mar 18, 2026

Aug Analyst Calls: What is the long term forecast for Genelux Corporation stockMarket Trend Review & Free Verified High Yield Trade Plans - baoquankhu1.vn

Mar 18, 2026

Mar 07, 2026